SH Khoo, R Fitzgerald, T Fletcher… - Journal of …, 2021 - ncbi.nlm.nih.gov
Optimal dose and safety of molnupiravir in patients with early SARS-CoV-2: a Phase I, open-label,
dose-escalating, randomized controlled study - PMC Back to Top Skip to main content NIH …